Novel applications for serum procalcitonin testing in clinical practice

References

• Pilotto A, Dini S, Daragjati J, et al. Combined use of the multidimensional prognostic index (MPI) and procalcitonin serum levels in predicting 1-month mortality risk in older patients hospitalized with community-acquired pneumonia (CAP): a prospective study. Aging Clin Exp Res. 2017.
   Web of Science ®Google Scholar
• Ceylan B, Arslan F, Sipahi OR, et al. Variables determining mortality in patients with Acinetobacter baumannii meningitis/ventriculitis treated with intrathecal colistin. Clin Neurol Neurosurg. 2017;153:43–49.
   PubMed Web of Science ®Google Scholar
• Valent AM, Peticca K, DiMatteo A, et al. Pyelonephritis in pregnancy: prediction of prolonged hospitalization and maternal morbidity using prognostic scoring systems. Am J Perinatol. 2017;34(12):1212–1218.
   PubMed Web of Science ®Google Scholar
• Lindell, R.B., et al. High levels of morbidity and mortality among pediatric hematopoietic cell transplant recipients with severe sepsis: insights from the sepsis prevalence, outcomes, and therapies international point prevalence study. Pediatr Crit Care Med. 2017;18:1122-1129.
   PubMed Web of Science ®Google Scholar
• Rivers E. The outcome of patients presenting to the emergency department with severe sepsis or septic shock. Crit Care. 2006;10(4):154.
   PubMed Web of Science ®Google Scholar
• Rivers EP, Nguyen HB, Huang DT, et al. Early goal-directed therapy. Crit Care Med. 2004;32(1): 314–315. author reply 315.
   PubMed Web of Science ®Google Scholar
• Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368–1377.
   PubMed Web of Science ®Google Scholar
• Cohen J. Current clinical controversies in the management of sepsis. J R Coll Physicians Edinb. 2016;46(4):263–269.
   PubMedGoogle Scholar
• Domínguez-Comesaña E, Ballinas-Miranda JR. Procalcitonin as a marker of intra-abdominal infection. Cir Cir. 2014;82(2):231–239.
   PubMed Web of Science ®Google Scholar
• Reinhart K, Bloos F. Procalcitonin-guided antimicrobial therapy-all about the algorithm-reply. JAMA Intern Med. 2017;177(1):142–143.
   PubMed Web of Science ®Google Scholar
• Van Der Maas ME, Mantjes G, Steuten LMG. Procalcitonin biomarker algorithm reduces antibiotic prescriptions, duration of therapy, and costs in chronic obstructive pulmonary disease: a comparison in The Netherlands, Germany, and the United Kingdom. Omics. 2017;21(4):232–243.
   PubMed Web of Science ®Google Scholar
• Van Oers JAH, Nijsten MW, Girbes AR. Procalcitonin-guided antimicrobial therapy-all about the algorithm. JAMA Intern Med. 2017;177(1):142.
   PubMed Web of Science ®Google Scholar
• Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta. 2002;323(1–2):17–29.
   PubMed Web of Science ®Google Scholar
• Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994;79(6):1605–1608.
   PubMed Web of Science ®Google Scholar
• Linscheid P, Seboek D, Schaer DJ, et al. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med. 2004;32(8):1715–1721.
   PubMed Web of Science ®Google Scholar
• Page AE, Sashittal SG, Chatzizacharias NA, et al. The role of laparoscopic surgery in the management of children and adolescents with inflammatory bowel disease. Medicine (Baltimore). 2015;94(21):e2264.
   PubMed Web of Science ®Google Scholar
• Karakousis PC, Sifakis FG, De Oca RM, et al. U.S. medical resident familiarity with national tuberculosis guidelines. BMC Infect Dis. 2007;7:137.
   PubMed Web of Science ®Google Scholar
• Kutz A, Grolimund E, Christ-Crain M, et al. Pre-analytic factors and initial biomarker levels in community-acquired pneumonia patients. BMC Anesthesiol. 2014;14:102.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Christ-Crain M, Albrich W, et al. Guidance of antibiotic therapy with procalcitonin in lower respiratory tract infections: insights into the ProHOSP study. Virulence. 2010;1(2):88–92.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Suter-Widmer I, Chaudri A, et al. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J. 2011;37(2):384–392.
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174(1):84–93.
   PubMed Web of Science ®Google Scholar
• Boucher BA. Procalcitonin: clinical tool or laboratory curiosity? Crit Care Med. 2000;28(4):1224–1225.
   PubMed Web of Science ®Google Scholar
• Kuse ER, Langefeld I, Jaeger K, et al. Procalcitonin in fever of unknown origin after liver transplantation: a variable to differentiate acute rejection from infection. Crit Care Med. 2000;28(2):555–559.
   PubMed Web of Science ®Google Scholar
• Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36(3):941–952.
   PubMed Web of Science ®Google Scholar
• Kylänpää-Bäck ML, Takala A, Kemppainen EA, et al. Procalcitonin, soluble interleukin-2 receptor, and soluble E-selectin in predicting the severity of acute pancreatitis. Crit Care Med. 2001;29(1):63–69.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Affolter B, Hunziker S, et al. Serum procalcitonin, C-reactive protein and white blood cell levels following hypothermia after cardiac arrest: a retrospective cohort study. Eur J Clin Invest. 2010;40(4):376–381.
   PubMed Web of Science ®Google Scholar
• Moyer MW. New biomarkers sought for improving sepsis management and care. Nat Med. 2012;18(7):999.
   PubMed Web of Science ®Google Scholar
• Dahaba AA, Rehak PH, List WF. Procalcitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Intensive Care Med. 2003;29(4):579–583.
   PubMed Web of Science ®Google Scholar
• Contou D, d’Ythurbide G, Messika J, et al. Description and predictive factors of infection in patients with chronic kidney disease admitted to the critical care unit. J Infect. 2014;68(2):105–115.
   PubMed Web of Science ®Google Scholar
• Herget-Rosenthal S, Klein T, Marggraf G, et al. Modulation and source of procalcitonin in reduced renal function and renal replacement therapy. Scand J Immunol. 2005;61(2):180–186.
   PubMed Web of Science ®Google Scholar
• Lavín-Gómez BA, Palomar-Fontanet R, Gago-Fraile M, et al. Inflammation markers, chronic kidney disease, and renal replacement therapy. Adv Perit Dial. 2011;27:33–37.
   PubMedGoogle Scholar
• Herget-Rosenthal S, Marggraf G, Pietruck F, et al. Procalcitonin for accurate detection of infection in haemodialysis. Nephrol Dial Transplant. 2001;16(5):975–979.
   PubMed Web of Science ®Google Scholar
• Dumea R, Siriopol D, Hogas S, et al. Procalcitonin: diagnostic value in systemic infections in chronic kidney disease or renal transplant patients. Int Urol Nephrol. 2014;46(2):461–468.
   PubMed Web of Science ®Google Scholar
• Sitter T, Schmidt M, Schneider S, et al. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. J Nephrol. 2002;15(3):297–301.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Burchardi C, Sitter T, et al. Procalcitonin in patients undergoing chronic hemodialysis. Nephron. 2000;84(2):187–188.
   PubMed Web of Science ®Google Scholar
• Eberhard OK, Haubitz M, Brunkhorst FM, et al. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum. 1997;40(7):1250–1256.
   PubMed Web of Science ®Google Scholar
• Level C, Chauveau P, Delmas Y, et al. Procalcitonin: a new marker of inflammation in haemodialysis patients? Nephrol Dial Transplant. 2001;16(5):980–986.
   PubMed Web of Science ®Google Scholar
• Visvardis G, Griveas I, Fleva A, et al. Relevance of procalcitonin levels in comparison to other markers of inflammation in hemodialysis patients. Ren Fail. 2005;27(4):429–434.
   PubMed Web of Science ®Google Scholar
• Grace E, Turner RM. Use of procalcitonin in patients with various degrees of chronic kidney disease including renal replacement therapy. Clin Infect Dis. 2014;59(12):1761–1767.
   PubMed Web of Science ®Google Scholar
• Davidson RJ. NKF-DOQI clinical practice guidelines for hemodialysis adequacy. National Kidney Foundation. Am J Kidney Dis. 1997;30(Suppl 3):SS15–SS66.
   Web of Science ®Google Scholar
• Lorton F, Veinberg F, Ielsch D, et al. Procalcitonin serum levels in children undergoing chronic haemodialysis. Pediatr Nephrol. 2007;22(3):430–435.
   PubMed Web of Science ®Google Scholar
• Lu X-L, Xiao Z-H, Yang M-Y, et al. Diagnostic value of serum procalcitonin in patients with chronic renal insufficiency: a systematic review and meta-analysis. Nephrol Dial Transplant. 2013;28(1):122–129.
   PubMed Web of Science ®Google Scholar
• Montagnana M, Lippi G, Tessitore N, et al. Procalcitonin values after dialysis is closely related to type of dialysis membrane. Scand J Clin Lab Invest. 2009;69(6):703–707.
   PubMed Web of Science ®Google Scholar
• Lee WS, Kang DW, Back JH, et al. Cutoff value of serum procalcitonin as a diagnostic biomarker of infection in end-stage renal disease patients. Korean J Intern Med. 2015;30(2):198–204.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick B, Schuler C, Leggett RE, et al. Nitrotyrosine density of procalcitonin in patients on chronic hemodialysis: procalcitonin is not related with increased serum calcitonin. ISRN Urol. 2012;2012:431859.
   PubMedGoogle Scholar
• Opatrná S, Klaboch J, Opatrný K, et al. Procalcitonin levels in peritoneal dialysis patients. Perit Dial Int. 2005;25(5):470–472.
   PubMed Web of Science ®Google Scholar
• Guz G, Colak B, Hizel K, et al. Procalcitonin and conventional markers of inflammation in peritoneal dialysis patients and peritonitis. Perit Dial Int. 2006;26(2):240–248.
   PubMed Web of Science ®Google Scholar
• Steinbach G, Bölke E, Grünert A, et al. Procalcitonin in patients with acute and chronic renal insufficiency. Wien Klin Wochenschr. 2004;116(24):849–853.
   PubMed Web of Science ®Google Scholar
• Maruna P, Nedelníková K, Gürlich R. Physiology and genetics of procalcitonin. Physiol Res. 2000;49(Suppl 1):S57–S61.
   PubMed Web of Science ®Google Scholar
• Reinhart K, Meisner M. Biomarkers in the critically ill patient: procalcitonin. Crit Care Clin. 2011;27(2):253–263.
   PubMed Web of Science ®Google Scholar
• Herbelin A, Nguyen AT, Zingraff J, et al. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int. 1990;37(1):116–125.
   PubMed Web of Science ®Google Scholar
• Oberhoffer M, Stonans I, Russwurm S, et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med. 1999;134(1):49–55.
   PubMed Web of Science ®Google Scholar
• Balog A, Ocsovszki I, Mándi Y. Flow cytometric analysis of procalcitonin expression in human monocytes and granulocytes. Immunol Lett. 2002;84(3):199–203.
   PubMed Web of Science ®Google Scholar
• Oberhoffer M, Vogelsang H, Jäger L, et al. Katacalcin and calcitonin immunoreactivity in different types of leukocytes indicate intracellular procalcitonin content. J Crit Care. 1999;14(1):29–33.
   PubMed Web of Science ®Google Scholar
• Linscheid P, Seboek D, Nylen ES, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology. 2003;144(12):5578–5584.
   PubMed Web of Science ®Google Scholar
• Lai KN, Leung JCK. Inflammation in peritoneal dialysis. Nephron Clin Pract. 2010;116(1):c11–c18.
   PubMedGoogle Scholar
• Panichi V, Migliori M, De Pietro S, et al. The link of biocompatibility to cytokine production. Kidney Int Suppl. 2000;76:S96–S103.
   PubMed Web of Science ®Google Scholar
• Hoffmann U, Fischereder M, Marx M, et al. Induction of cytokines and adhesion molecules in stable hemodialysis patients: is there an effect of membrane material? Am J Nephrol. 2003;23(6):442–447.
   PubMed Web of Science ®Google Scholar
• Laude-Sharp M, Caroff M, Simard L, et al. Induction of IL-1 during hemodialysis: transmembrane passage of intact endotoxins (LPS). Kidney Int. 1990;38(6):1089–1094.
   PubMed Web of Science ®Google Scholar
• Lonnemann G, Haubitz M, Schindler R. Hemodialysis-associated induction of cytokines. Blood Purif. 1990;8(4):214–222.
   PubMed Web of Science ®Google Scholar
• Caglar K, Peng Y, Pupim LB, et al. Inflammatory signals associated with hemodialysis. Kidney Int. 2002;62(4):1408–1416.
   PubMed Web of Science ®Google Scholar
• Haeffner-Cavaillon N, Jahns G, Poignet JL, et al. Induction of interleukin-1 during hemodialysis. Kidney Int Suppl. 1993;39:S139–S143.
   PubMed Web of Science ®Google Scholar
• Sinha M, Desai S, Mantri S, et al. Procalcitonin as an adjunctive biomarker in sepsis. Indian J Anaesth. 2011;55(3):266–270.
   PubMedGoogle Scholar
• Jeeha R, Skinner DL, De Vasconcellos K, et al. Serum procalcitonin levels predict acute kidney injury in critically ill patients. Nephrology (Carlton). 2017;54:2111-2119.
   PubMed Web of Science ®Google Scholar
• Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323(4):236–241.
   PubMed Web of Science ®Google Scholar
• Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 1995;92(6):1479–1486.
   PubMed Web of Science ®Google Scholar
• Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102(25):3060–3067.
   PubMed Web of Science ®Google Scholar
• Miettinen KH, Lassus J, Harjola V-P, et al. Prognostic role of pro- and anti-inflammatory cytokines and their polymorphisms in acute decompensated heart failure. Eur J Heart Fail. 2008;10(4):396–403.
   PubMed Web of Science ®Google Scholar
• Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107(11):1486–1491.
   PubMed Web of Science ®Google Scholar
• Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999;353(9167):1838–1842.
   PubMed Web of Science ®Google Scholar
• Page VJ, Casarin A. Missing link or not, mobilise against delirium. Crit Care. 2014;18(1):R4.
   PubMed Web of Science ®Google Scholar
• Anker SD, Egerer KR, Volk HD, et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol. 1997;79(10):1426–1430.
   PubMed Web of Science ®Google Scholar
• Mollar A, Villanueva MP, Carratalá A, et al. Determinants of procalcitonin concentration in acute heart failure. Int J Cardiol. 2014;177(2):532–534.
   PubMed Web of Science ®Google Scholar
• Bozkurt B, Kribbs SB, Clubb FJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97(14):1382–1391.
   PubMed Web of Science ®Google Scholar
• Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263–271.
   PubMed Web of Science ®Google Scholar
• Boulogne M, Sadoune M, Launay JM, et al. Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. Int J Cardiol. 2017;226:53–59.
   PubMed Web of Science ®Google Scholar
• Canbay A, Celebi OO, Celebi S, et al. Procalcitonin: a marker of heart failure. Acta Cardiol. 2015;70(4):473–478.
   PubMed Web of Science ®Google Scholar
• Maisel AS, Choudhary R. Biomarkers in acute heart failure–state of the art. Nat Rev Cardiol. 2012;9(8):478–490.
   PubMed Web of Science ®Google Scholar
• Travaglino F, Russo V, De Berardinis B, et al. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial. Am J Emerg Med. 2014;32(4):334–341.
   PubMed Web of Science ®Google Scholar
• Villanueva MP, Mollar A, Palau P, et al. Procalcitonin and long-term prognosis after an admission for acute heart failure. Eur J Intern Med. 2015;26(1):42–48.
   PubMed Web of Science ®Google Scholar
• Loncar G, Tscholl V, Tahirovic E, et al. Should procalcitonin be measured routinely in acute decompensated heart failure? Biomark Med. 2015;9(7):651–659.
   PubMed Web of Science ®Google Scholar
• Demissei BG, Cleland JG, O’Connor CM, et al. Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. Int J Cardiol. 2016;204:164–171.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Kutz A, Grolimund E, et al. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. Int J Cardiol. 2014;175(3):464–472.
   PubMed Web of Science ®Google Scholar
• Hug A, Mürle B, Dalpke A, et al. Usefulness of serum procalcitonin levels for the early diagnosis of stroke-associated respiratory tract infections. Neurocrit Care. 2011;14(3):416–422.
   PubMed Web of Science ®Google Scholar
• Wang C, Gao L, Zhang Z-G, et al. Procalcitonin is a stronger predictor of long-term functional outcome and mortality than high-sensitivity c-reactive protein in patients with ischemic stroke. Mol Neurobiol. 2016;53(3):1509–1517.
   PubMed Web of Science ®Google Scholar
• Remskar M, Horvat M, Hojker S, et al. Procalcitonin in patients with acute myocardial infarction. Wien Klin Wochenschr. 2002;114(5–6):205–210.
   PubMed Web of Science ®Google Scholar
• Sinning CR, Sinning J-M, Schulz A, et al. Association of serum procalcitonin with cardiovascular prognosis in coronary artery disease. Circ J. 2011;75(5):1184–1191.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Daniels LB, Kulkarni P, et al. Procalcitonin: a new biomarker for the cardiologist. Int J Cardiol. 2016;223:390–397.
   PubMed Web of Science ®Google Scholar
• Pouriki S, Vrioni G, Sambatakou H, et al. Intestinal colonization with resistant bacteria: a prognostic marker of mortality in decompensated cirrhosis. Eur J Clin Microbiol Infect Dis. 2017.
   PubMed Web of Science ®Google Scholar
• Viallon A, Zeni F, Pouzet V, et al. Serum and ascitic procalcitonin levels in cirrhotic patients with spontaneous bacterial peritonitis: diagnostic value and relationship to pro-inflammatory cytokines. Intensive Care Med. 2000;26(8):1082–1088.
   PubMed Web of Science ®Google Scholar
• Lesińska M, Hartleb M, Gutkowski K, et al. Procalcitonin and macrophage inflammatory protein-1 beta (MIP-1β) in serum and peritoneal fluid of patients with decompensated cirrhosis and spontaneous bacterial peritonitis. Adv Med Sci. 2014;59(1):52–56.
   PubMed Web of Science ®Google Scholar
• Connert S, Stremmel W, Elsing C. Procalcitonin is a valid marker of infection in decompensated cirrhosis. Z Gastroenterol. 2003;41(2):165–170.
   PubMed Web of Science ®Google Scholar
• Koutsounas I, Kaltsa G, Siakavellas SI, et al. Markers of bacterial translocation in end-stage liver disease. World J Hepatol. 2015;7(20):2264–2273.
   PubMed Web of Science ®Google Scholar
• Lin K-H, Wang F-L, Wu M-S, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: a systematic review and meta-analysis. Diagn Microbiol Infect Dis. 2014;80(1):72–78.
   PubMed Web of Science ®Google Scholar
• Elefsiniotis IS, Skounakis M, Vezali E, et al. Clinical significance of serum procalcitonin levels in patients with acute or chronic liver disease. Eur J Gastroenterol Hepatol. 2006;18(5):525–530.
   PubMed Web of Science ®Google Scholar
• Thursz MR, Forrest EH, Ryder S. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;373(3):282–283.
   PubMed Web of Science ®Google Scholar
• Oruc N, Ozutemiz O, Yuce G, et al. Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study. BMC Gastroenterol. 2009;9:16.
   PubMed Web of Science ®Google Scholar
• Lazzarotto C, Ronsoni MF, Fayad L, et al. Acute phase proteins for the diagnosis of bacterial infection and prediction of mortality in acute complications of cirrhosis. Ann Hepatol. 2013;12(4):599–607.
   PubMed Web of Science ®Google Scholar
• Bota DP, Van Nuffelen M, Zakariah AN, et al. Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver. J Lab Clin Med. 2005;146(6):347–351.
   PubMed Web of Science ®Google Scholar
• Chirapongsathorn S, Bunraksa W, Chaiprasert A, et al. Adding C-reactive protein and procalcitonin to the MELD score improves mortality prediction in patients with complications of cirrhosis. J Gastroenterol Hepatol. 2017;21:1543-1560.
   PubMed Web of Science ®Google Scholar
• Gallego M, Pomares X, Capilla S, et al. C-reactive protein in outpatients with acute exacerbation of COPD: its relationship with microbial etiology and severity. Int J Chron Obstruct Pulmon Dis. 2016;11:2633–2640.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Becker KL, Swinburne AJ, et al. Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note. Int J Chron Obstruct Pulmon Dis. 2012;7:127–135.
   PubMed Web of Science ®Google Scholar
• Gilbert D. Discriminatory value of procalcitonin. Am J Respir Crit Care Med. 2011;184(10): 1210. author reply 1210-1.
   PubMed Web of Science ®Google Scholar
• Gilbert DN. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol. 2010;48(7):2325–2329.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Curtis JL. Procalcitonin-guided antibiotic therapy in COPD exacerbations: closer but not quite there. Chest. 2007;131(1):1–2.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Clark TW, Reid C, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest. 2011;139(6):1410–1418.
   PubMed Web of Science ®Google Scholar
• Kherad O, Kaiser L, Bridevaux P-O, et al. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest. 2010;138(4):896–904.
   PubMed Web of Science ®Google Scholar
• Daubin C, Parienti J-J, Fradin S, et al. Procalcitonin levels and bacterial aetiology among COPD patients admitted to the ICU with severe pneumonia: a prospective cohort study. BMC Infect Dis. 2009;9:157.
   PubMed Web of Science ®Google Scholar
• Daubin C, Parienti -J-J, Vabret A, et al. Procalcitonin levels in acute exacerbation of COPD admitted in ICU: a prospective cohort study. BMC Infect Dis. 2008;8:145.
   PubMed Web of Science ®Google Scholar
• Liu H, Luo Z, Liu L, et al. Early kinetics of procalcitonin in predicting surgical outcomes in type A aortic dissection patients. Chin Med J (Engl). 2017;130(10):1175–1181.
   PubMed Web of Science ®Google Scholar
• Póvoa P, Martin-Loeches I, Ramirez P, et al. Biomarkers kinetics in the assessment of ventilator-associated pneumonia response to antibiotics - results from the BioVAP study. J Crit Care. 2017;41:91–97.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Bretscher C, Bernasconi L, et al. Overview of procalcitonin assays and procalcitonin-guided protocols for the management of patients with infections and sepsis. Expert Rev Mol Diagn. 2017;17(6):593–601.
   PubMed Web of Science ®Google Scholar
• Schuetz, P., et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017;10:CD007498.
   PubMedGoogle Scholar
• Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2017;14:865-880.
   Web of Science ®Google Scholar
• He D, Zhang Y, Zhang B, et al. Serum procalcitonin levels are associated with clinical outcome in intracerebral hemorrhage. Cell Mol Neurobiol. 2017.
   Web of Science ®Google Scholar
• Ulm L, Hoffmann S, Nabavi D, et al. The randomized controlled STRAWINSKI trial: procalcitonin-guided antibiotic therapy after stroke. Front Neurol. 2017;8:153.
   PubMed Web of Science ®Google Scholar
• Brocca, A., et al. Elevated levels of procalcitonin and interleukin-6 are linked with postoperative complications in cardiac surgery. Scand J Surg. 2017. 1457496916683096.
   PubMed Web of Science ®Google Scholar
• Hayati F, Mohd Azman ZA, Nasuruddin DN, et al. Serum procalcitonin predicts anastomotic leaks in colorectal surgery. Asian Pac J Cancer Prev. 2017;18(7):1821–1825.
   PubMedGoogle Scholar
• Woliński K, Kaznowski J, Klimowicz A, et al. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen. Endokrynol Pol. 2017;68(4):434–437.
   PubMed Web of Science ®Google Scholar
• Boursier G, Avignon A, Kuster N, et al. Procalcitonin, an independent marker of abdominal fat accumulation in obese patients. Clin Lab. 2016;62(3):435–441.
   PubMed Web of Science ®Google Scholar
• Chenevier-Gobeaux C, Trabattoni E, Elfassy Y, et al. Decisional procalcitonin thresholds are not adapted to elderly patients admitted to the emergency room. Biomarkers. 2012;17(5):477–481.
   PubMed Web of Science ®Google Scholar